Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype1

Brady, 1967, Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency, N Engl J Med, 276, 1163, 10.1056/NEJM196705252762101 Desnick, 1973, Fabry disease: Enzymatic diagnosis of hemizygotes and heterozygotes. α-Galactosidase activities in plasma, serum, urine and leukocytes, J Lab Clin Med, 81, 157 Desnick, 2001, α-Galactosidase A deficiency: Fabry disease, 3733 McNary, 1965, A morphological study of the renal lesion in angiokeratoma corporis diffusum universale (Fabry's disease), J Urol, 93, 641, 10.1016/S0022-5347(17)63848-5 Pabico, 1973, Renal pathologic lesions and functional alterations in a man with Fabry's disease, Am J Med, 55, 415, 10.1016/0002-9343(73)90140-X Desnick, 1976, Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies, Circulation, 54, 818, 10.1161/01.CIR.54.5.818 Willard, 2001, The sex chromosome and X chromosome inactivation, 1191 Elleder, 1990, Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy, Virchows Arch A Pathol Anat Histopathol, 417, 449, 10.1007/BF01606034 von Scheidt, 1991, An atypical variant of Fabry's disease with manifestations confined to the myocardium, N Engl J Med, 324, 395, 10.1056/NEJM199102073240607 Nagao, 1991, Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of α-galactosidase A, Clin Genet, 39, 233, 10.1111/j.1399-0004.1991.tb03018.x Nakao, 1995, An atypical variant of Fabry's disease in men with left ventricular hypertrophy, N Engl J Med, 333, 288, 10.1056/NEJM199508033330504 Sachdev, 2002, Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy, Circulation, 105, 1407, 10.1161/01.CIR.0000012626.81324.38 Schiffmann, 2000, Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease, Proc Natl Acad Sci USA, 97, 365, 10.1073/pnas.97.1.365 Schiffmann, 2001, Enzyme replacement therapy in Fabry disease: A randomized controlled trial, JAMA, 285, 2743, 10.1001/jama.285.21.2743 Eng, 2001, A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies, Am J Hum Genet, 68, 711, 10.1086/318809 Eng, 2001, Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease, N Engl J Med, 345, 9, 10.1056/NEJM200107053450102 Frustaci, 2001, Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy, N Engl J Med, 345, 25, 10.1056/NEJM200107053450104 Desnick, 2002, Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders, Nat Rev Genet, 3, 954, 10.1038/nrg963 Shelley, 1995, Painful fingers, heat intolerance, and telangiectases of the ear: Easily ignored childhood signs of Fabry disease, Pediatr Dermatol, 12, 215, 10.1111/j.1525-1470.1995.tb00161.x Felner, 1990, Echocardiography, 1990 Mayes, 1981, Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry's disease, Clin Chim Acta, 112, 247, 10.1016/0009-8981(81)90384-3 Vance, 1969, Concentrations of glycosyl ceramides in plasma and red cells in Fabry's disease, a glycolipid lipidosis, J Lipid Res, 10, 188, 10.1016/S0022-2275(20)42667-7 Eng, 1993, Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease, Am J Hum Genet, 53, 1186 Scriver, 2001 Yoshitama, 2001, Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry's disease, Am J Cardiol, 87, 71, 10.1016/S0002-9149(00)01275-3 Eng, 1997, Fabry disease: Thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes, Mol Med, 3, 174, 10.1007/BF03401671 Ishii, 1992, Point mutations in the upstream region of the α-galactosidase A gene exon 6 in an atypical variant of Fabry disease, Hum Genet, 89, 29, 10.1007/BF00207037 Eng, 1994, Fabry disease: Twenty-three mutations including sense and antisense CpG alterations and identification of a deletion hot-spot in the α-galactosidase A gene, Hum Mol Genet, 3, 1795, 10.1093/hmg/3.10.1795 Ashton-Prolla, 2000, 22 novel mutations in the α-galactosidase A gene and genotype/phenotype correlations including mild hemizygotes and severely affected heterozygotes, J Invest Med, 48, 227 Ledvinova, 1997, Blood group B glycosphingolipids in α-galactosidase deficiency (Fabry disease): Influence of secretor status, Biochim Biophys Acta, 1345, 180, 10.1016/S0005-2760(96)00175-0 Clarke, 1971, Ceramide trihexosidosis (Fabry's disease) without skin lesions, N Engl J Med, 284, 233, 10.1056/NEJM197102042840503 Sobh, 1988, Value of renal biopsy in chronic renal failure, Int Urol Nephrol, 20, 77, 10.1007/BF02583035 Akiba, 2001, An overview of dialysis treatment in Japan (as of Dec 31, 2000), Jpn Soc Dial Ther, 81, 1 Utsumi, 2002, Fabry disease in patients receiving maintenance dialysis, Clin Exp Nephrol, 4, 49, 10.1007/s101570050061 Centers of Medicare and Medicaid Services, 2002, 2001 annual report: End stage renal disease clinical performance measures project, Am J Kidney Dis, 39, S1 U.S. Renal Data System, 2001, UADR 2001 annual data report Spada, 2002, Screening for Fabry disease in end-stage nephropathies, J Inherit Metab Dis, 25, 113 MacDermot, 2001, Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females, J Med Genet, 38, 769, 10.1136/jmg.38.11.769 Whybra, 2001, Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes, J Inherit Metab Dis, 24, 715, 10.1023/A:1012993305223 Thadhani, 2002, Patients with Fabry disease on dialysis in the United States, Kidney Int, 61, 249, 10.1046/j.1523-1755.2002.00097.x